• R Hehlmann, H Heimpel, D K Hossfeld, J Hasford, H J Kolb, H Löffler, H Pralle, W Queisser, A Hochhaus, A Tichelli, W Fett, N Schmitz, A Reiter, M Griesshammer, W Pfeifer, M Bümler, T Kamp, A Tobler, H Eimermacher, R Kuse, U Berger, and H Ansari.
• Klinikum Mannheim der Universität Heidelberg, Mannheim, Germany.
• Bone Marrow Transplant. 1996 May 1; 17 Suppl 3: S21-4.

AbstractIt is the long-term goal of the German CML Study Group and of the Süddeutsche Hämoblastosegruppe (SHG) to improve survival of patients with chronic myelogenous leukemia (CML). In a first randomized study (CML Study I) monotherapies with hydroxyurea or interferon alpha (IFN-alpha) were compared with a standard busulfan regimen with regard to duration of the chronic phase and survival. The main results of this study were published, 1-3 and a long-term follow up is planned. In a second randomized study the effect of the combination of IFN-alpha and hydroxyurea versus hydroxyurea monotherapy on survival is being investigated. This paper provides a first preliminary report on the study concept, patient recruitment, state of documentation and initial patients' characteristics 9 months after closure of the study.

18 keywords...

hide…